New treatment for drug-resistant bacterial infections
Host Directed Orynotide for MDR Gram Negative Bacterial Infections
This study is testing a new treatment called Orynotide™ MTD12813 to help people with tough bacterial infections that don't respond to regular antibiotics, especially those caused by certain resistant germs.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Southern California NIH-funded |
| Lab location | 1 site (Los Angeles, UNITED STATES) |
| Project ID | NIH-10892236 on NIH RePORTER |
What this research studies
This research focuses on developing a novel peptide called Orynotide™ MTD12813 to treat multidrug resistant Gram-negative bacterial infections, particularly those caused by carbapenem-resistant Enterobacteriaceae. The approach involves leveraging the unique properties of θ-defensins, which are naturally occurring peptides found in certain primates, to create effective antimicrobial agents. The research aims to advance these peptides through preclinical development, assessing their effectiveness in models of severe bacterial infections. Patients with these infections may benefit from new treatment options that could be more effective than current antibiotics.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with infections caused by multidrug resistant Gram-negative bacteria, particularly those resistant to carbapenems.
Not a fit: Patients with infections caused by bacteria that are not multidrug resistant or those who do not have Gram-negative bacterial infections may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new treatment option for patients suffering from severe infections caused by drug-resistant bacteria.
How similar studies have performed: Other research has shown promise in developing similar host-directed antimicrobial therapies, indicating potential for success in this novel approach.
Where this research is happening
Los Angeles, UNITED STATES
- University of Southern California — Los Angeles, United States (Active)
Researchers
- Principal investigator: Schaal, Justin Blaine — University of Southern California
- Study coordinator: Schaal, Justin Blaine
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.